Pharsight

Klisyri generic

Klisyri is a topical treatment for actinic keratosis of the face or scalp that is owned by Almirall. This drug contains the active ingredient tirbanibulin and was first authorised for market use on 14 December, 2020.

When will Klisyri generic be available?

The generic version of Klisyri is estimated to be released after 7 September, 2038. This is largely influenced by the fact that Klisyri's last patent, namely 'Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide', will expire on the same date.

Klisyri uses

Klisyri, with its active ingredient tirbanibulin, is used as a topical treatment for actinic keratosis, a condition that causes rough, scaly patches on your skin resulting from years of exposure to the sun, primarily on the face or scalp.

Klisyri patent expiration

Klisyri holds a total of 8 patents, none of which have expired as of now. The drug patent challenges against Klisyri can start from 14 December, 2024. The last patent for Klisyri is due to expire on 7 September, 2038, possibly paving the way for the release of Klisyri generic. Below are the details of the patent:

Klisyri dosage

Want to ask something?